Tak 187

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 526405

CAS#: 155432-64-7

Description: Tak 187 is a long-lasting ergosterol biosynthesis inhibitor.


Chemical Structure

img
Tak 187
CAS# 155432-64-7

Theoretical Analysis

MedKoo Cat#: 526405
Name: Tak 187
CAS#: 155432-64-7
Chemical Formula: C23H20F6N6O3
Exact Mass: 542.15
Molecular Weight: 542.442
Elemental Analysis: C, 50.93; H, 3.72; F, 21.01; N, 15.49; O, 8.85

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Tak 187, Tak187, Tak-187

IUPAC/Chemical Name: 2-(2-(2,4-Difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl)propyl)-4-(4-(2,2,3,3-tetrafluoropropoxy)phenyl)-3(2H,4H)-1,2,4-triazolone

InChi Key: CBHTUKXHISWMTH-UHFFFAOYSA-N

InChi Code: InChI=1S/C23H20F6N6O3/c1-14(22(37,9-33-12-30-11-31-33)18-7-2-15(24)8-19(18)25)35-21(36)34(13-32-35)16-3-5-17(6-4-16)38-10-23(28,29)20(26)27/h2-8,11-14,20,37H,9-10H2,1H3

SMILES Code: O=C1N(C(C)C(O)(C2=CC=C(F)C=C2F)CN3N=CN=C3)N=CN1C4=CC=C(OCC(F)(F)C(F)F)C=C4

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 542.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Corrales M, Cardozo R, Segura MA, Urbina JA, Basombrío MA. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease. Antimicrob Agents Chemother. 2005 Apr;49(4):1556-60. PubMed PMID: 15793138; PubMed Central PMCID: PMC1068647.

2: Urbina JA, Payares G, Sanoja C, Molina J, Lira R, Brener Z, Romanha AJ. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int J Antimicrob Agents. 2003 Jan;21(1):39-48. PubMed PMID: 12507836.

3: Urbina JA. Specific treatment of Chagas disease: current status and new developments. Curr Opin Infect Dis. 2001 Dec;14(6):733-41. Review. PubMed PMID: 11964893.

4: Kitazaki T, Tasaka A, Hosono H, Matsushita Y, Itoh K. Optically active antifungal azoles. IX. An alternative synthetic route for 2-[(1R,2R)-2-(2,4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4- triazol-1-yl)propyl]-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]- 3(2H,4H)-1,2,4-triazolone and its analogs. Chem Pharm Bull (Tokyo). 1999 Mar;47(3):360-8. PubMed PMID: 10212386.

5: Schell WA, De Almeida GM, Dodge RK, Okonogi K, Perfect JR. In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans. Antimicrob Agents Chemother. 1998 Oct;42(10):2630-2. PubMed PMID: 9756767; PubMed Central PMCID: PMC105909.

6: Bartroli J, Turmo E, Algueró M, Boncompte E, Vericat ML, Conte L, Ramis J, Merlos M, García-Rafanell J, Forn J. New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones. J Med Chem. 1998 May 21;41(11):1869-82. PubMed PMID: 9599237.

7: Tasaka A, Kitazaki T, Tsuchimori N, Matsushita Y, Hayashi R, Okonogi K, Itoh K. Optically active antifungal azoles. VII. Synthesis and antifungal activity of stereoisomers of 2-[(1R,2R)-2-(2, 4-difluorophenyl)-2-hydroxy-1-methyl-3-(1H-1,2,4-triazol-1-yl) propyl]-4-[4-(2,2,3,3-tetrafluoropropoxy)phenyl]-3(2H,4H)-1,2,4-triazo lone (TAK-187). Chem Pharm Bull (Tokyo). 1997 Feb;45(2):321-6. PubMed PMID: 9118446.